Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$0.43 USD
0.00 (-0.16%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.42 -0.01 (-1.18%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Athira Pharma, Inc. (ATHA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.67 | $22.00 | $0.50 | 1,683.72% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Athira Pharma, Inc. comes to $7.67. The forecasts range from a low of $0.50 to a high of $22.00. The average price target represents an increase of 1% from the last closing price of $0.43.
Analyst Price Targets (3 )
Broker Rating
Athira Pharma, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 2.60 a month ago based on five recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 1 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 4 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 2.60 | 1.80 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/19/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Hold |
9/4/2024 | Rodman & RenshawCo. | Elemer Piros | Strong Buy | Hold |
9/4/2024 | JMP Securities | Jason N Butler | Strong Buy | Hold |
9/4/2024 | BTIG | Thomas Shrader | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 5 |
Average Target Price | $7.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -0.80 |
ATHA FAQs
Athira Pharma, Inc. (ATHA) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Athira Pharma, Inc. (ATHA) is $7.67. The current on short-term price targets is based on 1 reports.
The forecasts for Athira Pharma, Inc. (ATHA) range from a low of $.5 to a high of $22. The average price target represents a increase of $1683.72 from the last closing price of $.43.
The current UPSIDE for Athira Pharma, Inc. (ATHA) is 1683.72%
Based on short-term price targets offered by three analysts, the average price target for Athira Pharma, Inc. comes to $7.67. The forecasts range from a low of $0.50 to a high of $22.00. The average price target represents an increase of 1% from the last closing price of $0.43.